Scribd Logo
Upload

Welcome to Scribd!

  • 2.dose Response and Safety Study of Meloxicam Up To 22.5 MG Daily in Rheumatoid Arthritis - A 12 Week Multicenter, Double Blind, Dose Response Study V..

    Uploaded by

    kcordoba16
    25 views2 pages
    Descripcion dosis respuesta meloxicam en pacientes con AR

    Original Title

    2.Dose Response and Safety Study of Meloxicam Up to 22.5 Mg Daily in Rheumatoid Arthritis_ a 12 Week Multicenter, Double Blind, Dose Response Study v..

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    Descripcion dosis respuesta meloxicam en pacientes con AR

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    25 views2 pages

    2.dose Response and Safety Study of Meloxicam Up To 22.5 MG Daily in Rheumatoid Arthritis - A 12 Week Multicenter, Double Blind, Dose Response Study V..

    Uploaded by

    kcordoba16
    Descripcion dosis respuesta meloxicam en pacientes con AR

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 2

    30/3/2017 Doseresponseandsafetystudyofmeloxicamupto22.5mgdailyinrheumatoidarthritis:a12weekmulticenter,doubleblind,doseresponsestudyv...

    PubMed

    Format:Abstract Fulltextlinks

    JRheumatol.2002Mar29(3):43646.

    Doseresponseandsafetystudyofmeloxicamupto22.5mgdailyin
    rheumatoidarthritis:a12weekmulticenter,doubleblind,dose
    responsestudyversusplaceboanddiclofenac.
    FurstDE1,KolbaKS,FleischmannR,SilverfieldJ,GreenwaldM,RothS,HallDB,RoszkoPJMeloxicam
    RheumatoidArthritisInvestigators.

    Authorinformation

    Abstract
    OBJECTIVE: ThisPhaseIII,placeboandactivecontrolled,multicentertrialevaluatedtheefficacy
    andsafetyofmeloxicam7.5,15,and22.5mgdailyforthetreatmentofrheumatoidarthritis(RA).
    METHODS: A12week,randomized,doubleblind,doubledummy,parallelgrouptrialcompareddaily
    oralmeloxicam7.5,15,and22.5mgtoplacebo(negativecontrol)anddiclofenac75mgBID
    (positivecontrol).Atotalof894patients(18yearsofagewithconfirmedRAwhoflaredfollowingan
    NSAIDfreeperiod)wererandomizedtobetreated.Baselinescoresforallendpointsweresimilar
    amongthetreatmentgroups.Patientassessmentswereat0,2,4,8,and12weeksorearly
    termination.
    RESULTS: Alltreatmentgroupsdemonstratedsignificantimprovementfrombaseline(p<0.001).
    Meloxicam7.5and22.5mgwassignificantlysuperiortoplaceboinall5primaryefficacyendpoints
    (swollenjointcount,tenderjointcount,patientpain,patientandphysicianglobalallp<0.05).
    Diclofenac150mgwassuperiortoplacebofor4of5primaryefficacymeasures(allbutswollenjoint
    countp<0.05)andmeloxicam15mgwassuperiorfor3of5primaryendpoints(patientpainand
    patientandphysicianglobal).AUCofpatientglobal,patientpain,andmodifiedHealthAssessment
    Questionnairedemonstrateddoseresponse(p<0.04),whileAUCACR20showedaqualitative
    trendinthesamedirection.Therateofgastrointestinal(GI)eventsduringthe12weektrialforall
    dosesofmeloxicamanddiclofenacdidnotdiffersignificantlyfromplacebo(23.232.0%).GI
    withdrawalswerecomparableandnotsignificantlydifferentacrossalltreatmentgroups(4.35.7%).
    CONCLUSION: Thistrialdemonstratedadoseresponserelationshipformeloxicam7.5,15,and22.5
    mgusingAUCmeasurementofresponseforthetreatmentofRA.All3dosesofmeloxicam.and
    positivecontrol,wereeffectiveinthetreatmentofRA.TheoverallincidencerateofGIeventsdidnot
    differsignificantlyfromplaceboineitherthemeloxicamtreatmentgroupsorthepositivecontrol.

    PMID:11908554
    [IndexedforMEDLINE]

    https://www.ncbi.nlm.nih.gov/pubmed/11908554 1/2
    30/3/2017 Doseresponseandsafetystudyofmeloxicamupto22.5mgdailyinrheumatoidarthritis:a12weekmulticenter,doubleblind,doseresponsestudyv...P

    Publicationtypes,MeSHterms,Substances

    LinkOutmoreresources

    PubMedCommons PubMedCommonshome

    0comments
    HowtojoinPubMedCommons

    https://www.ncbi.nlm.nih.gov/pubmed/11908554 2/2

    You might also like